New York · 2025 Regular Session · Bill
S 6422: Relates to prescription labels for gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy
In committee Official data
- Introduced
- In committee
- Passed one chamber
- Passed both chambers
- Enacted
Last official action: ·Record last updated:
Plain-language summary
S 6422 is a bill introduced in the New York Senate on March 13, 2025. According to its official title, it concerns: Relates to prescription labels for gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy. Primary sponsor: Brad Hoylman-Sigal. It lists 1 additional sponsor. Most recent recorded action (March 13, 2025): REFERRED TO HIGHER EDUCATION.
Generated automatically from the official title, sponsor list, and status record only. It does not characterize the bill’s purpose or effects. How summaries are written
Official summary
Abstract published by the legislature (via Open States). Text as published by the legislature; reproduced verbatim.
Provides that prescription labels for gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy maybe include the name of the dispensing practice instead of the prescriber; provides for notice to patients.
Sponsors
Sponsors by party (alphabetical): Democratic/Working Families 1
| Name | Role | Party | Chamber | District |
|---|---|---|---|---|
| Brad Hoylman-Sigal | Primary sponsor | Not applicable (committee) | — | — |
| Jeremy Cooney | Co-sponsor | Democratic/Working Families | Senate | 56 |
“Support” is shown only as formal sponsorship recorded by the legislature. Roll-call votes are available on the official bill page.
Recent official actions
- REFERRED TO HIGHER EDUCATION